Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

@inproceedings{Sai2017SystematicDO,
  title={Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist},
  author={Wenbo Sai and Hong Tian and Kangmin Yang and Daoqi Tang and Jinxiao Bao and Yang Ge and Xiaoda Song and Yonghui Zhang and Cheng Luo and Xiangdong Gao and Wenbing Yao},
  booktitle={International journal of molecular sciences},
  year={2017}
}
Exendin-4 is a strong therapeutic candidate for the treatment of metabolic syndrome. Related receptor agonist drugs have been on the market since 2005. However, technical limitations and the pain caused by subcutaneous injection have severely limited patient compliance. The goal of the study is to investigate a biologically active exendin-4 analog could be… CONTINUE READING